Myriad Genetics (MYGN) Q1 2026: 100+ Rep Expansion Targets Cancer Share Gains Amid Launch Cycle
Myriad Genetics’ Q1 2026 results highlight the company’s pivot to cancer care and a major commercial expansion, with over 100 new sales hires targeting hereditary cancer and upcoming product launches. Leadership reaffirmed full-year guidance, banking on sales force productivity, new AI-enabled and prenatal offerings, and improved execution to drive a second-half acceleration. Investors face a pivotal period as Myriad seeks to convert pipeline momentum and commercial investment into sustainable profitable growth.
Summary
- Commercial Expansion: Over 100 new sales hires focus on hereditary cancer and launch readiness.
- Pipeline Activation: Three major launches—Precise MRD, Prolaris Plus AI, and First Gene—anchor growth strategy.
- Execution Watchpoint: Second-half growth hinges on sales force ramp and prenatal recovery.
Business Overview
Myriad Genetics, a molecular diagnostics company, generates revenue by providing genetic testing services across three core segments: cancer care continuum (hereditary and tumor testing), prenatal health (carrier and non-invasive prenatal screening), and mental health (pharmacogenomic testing through GeneSight). The business model centers on test volume, reimbursement rates, and expanding clinical adoption among providers and patients.
Performance Analysis
Q1 2026 revenue landed just above $200 million, within guidance, with year-over-year growth of 2%—a modest pace reflecting strong hereditary cancer and mental health offset by prenatal declines. Hereditary cancer testing volumes surged 14% year-over-year, driven by double-digit gains in both affected and unaffected populations, and now comprise the profit engine of the company. The mental health segment, led by GeneSight, posted 24% revenue growth on 7% volume increase, reflecting improved payer coverage and legislative tailwinds.
Conversely, prenatal health revenue fell 15% year-over-year due to lingering disruption from a new ordering system and tough comparisons, though sequential volume growth and stabilization signal potential for recovery. Gross margin improved slightly to 68.7%, benefiting from mix shift toward higher-margin cancer and mental health tests. Adjusted operating expenses rose $8 million year-over-year, reflecting a deliberate ramp in commercial and R&D investment ahead of anticipated product launches.
- Hereditary Cancer Drives Growth: 14% volume growth outpaced market, with strong share gains in unaffected populations.
- Mental Health Momentum: GeneSight’s payer wins and biomarker legislation fueled record ordering clinician base and revenue expansion.
- Prenatal Weakness Offset by Pipeline: First Gene launch and dedicated sales team aim to reverse segment decline in second half.
Management reaffirmed full-year revenue and profitability guidance, citing confidence in new commercial hires and upcoming launches to drive sequential acceleration.
Executive Commentary
"We are making significant investments in the cancer care continuum, including an expansion of our commercial capabilities and increased R&D spend on product development and clinical studies... There's still significant work ahead, but we have clear line of sight to how we will achieve our goals, including accelerated share gain and sustained profitable growth."
Sam Raha, President and Chief Executive Officer
"We remain confident in our full-year outlook and in the team's ability to execute as we progress through 2026."
Ben Wheeler, Chief Financial Officer
Strategic Positioning
1. Cancer Care Continuum as Core Focus
Myriad has reprioritized its entire organization around the cancer care continuum, concentrating resources, commercial expansion, and R&D on hereditary and molecular cancer testing. The company’s broad provider reach (serving nearly 3,500 oncologists) and recent product innovation position it to capture share in a market still underpenetrated.
2. Commercial Scale-Up and Field Specialization
The addition of over 100 account executives—primarily in oncology—marks a step change in sales capacity. Myriad has shifted to dedicated sales teams by portfolio (hereditary cancer, prenatal, mental health), aiming for sharper execution, deeper provider engagement, and higher productivity. Leadership expects a multi-quarter ramp to full productivity but sees this as essential for second-half acceleration.
3. Product Pipeline and Launch Cadence
Three launches—Precise MRD (minimal residual disease), Prolaris Plus AI (AI-enabled prostate cancer), and First Gene (integrated prenatal screen)—anchor the 2026 growth narrative. Early feedback on Precise MRD and First Gene has been positive, with both products positioned as differentiated in their respective markets. The pipeline is expected to not only regain lost share but also expand addressable markets.
4. Payer and Reimbursement Tailwinds
Improved reimbursement, especially for GeneSight and prenatal tests, underpins revenue per test and gross margin stability. Myriad is leveraging legislative momentum (biomarker laws) and payer wins to drive better coverage, with strategies to extend this playbook to cancer screening.
5. Operational Discipline Amid Investment Cycle
While operating expenses are rising with commercial and R&D investment, management signals strict cost control and a commitment to profitable growth. The company plans to phase expenses in line with volume growth, with operating leverage expected as new hires ramp and launches scale.
Key Considerations
This quarter marks a strategic inflection for Myriad, as the company seeks to translate commercial and pipeline investment into sustainable growth and margin expansion, while managing the complexity of multiple launches and a shifting payer landscape.
Key Considerations:
- Sales Force Productivity Ramp: Full benefit from 100+ new reps is expected over several quarters, making execution timing critical for second-half results.
- Prenatal Segment Recovery: First Gene’s launch is positioned as both a share regainer and a market expander, but operational and commercial execution must align.
- MRD and AI-Driven Innovation: Early clinical feedback and market interest in Precise MRD and Prolaris Plus AI could accelerate adoption, but commercial integration is still in formative stages.
- Reimbursement and Payer Dynamics: Continued ASP improvement depends on further payer wins and legislative support, with some modest long-term ASP headwinds acknowledged.
Risks
Execution risk is elevated as Myriad juggles multiple major launches, a rapidly expanded sales force, and a recovering prenatal segment. Timing mismatches between expense ramp and revenue realization could pressure margins. Market adoption for new products, especially in MRD and prenatal, is not guaranteed. Reimbursement environment remains variable, and ASP headwinds could resurface if payer support wanes or competitive pricing intensifies.
Forward Outlook
For Q2 2026, Myriad guided to:
- Sequential revenue growth in the low single digits
- Gross margin in the 68% to 69% range
For full-year 2026, management reaffirmed guidance:
- Revenue of $860 to $880 million
- Adjusted EBITDA of $37 to $49 million
Management expects second-half acceleration driven by commercial team ramp, prenatal recovery, and new product launches. Key drivers include hereditary cancer growth, GeneSight momentum, and First Gene’s market entry.
- Commercial productivity from new hires is expected to build through the year
- Product launches are timed to maximize second-half impact
Takeaways
Myriad’s growth hinges on commercial execution and pipeline conversion as it invests aggressively in cancer and prenatal innovation.
- Hereditary Cancer Remains the Profit Engine: Sustained double-digit volume growth and market share gains underpin financial stability and enable investment.
- Second-Half Acceleration Is a Test: Realization of full-year guidance depends on sales force productivity and successful launch execution, especially in prenatal and MRD.
- Investors Should Watch: Ramp of new hires, market adoption of First Gene and Precise MRD, and gross margin trends as leading indicators for profitable growth trajectory.
Conclusion
Myriad Genetics is in the midst of a high-stakes commercial and innovation cycle, with execution in cancer and prenatal segments set to define its 2026 trajectory. Investors will need to monitor sales ramp, launch adoption, and margin discipline as the company seeks to convert investment into durable, profitable growth.
Industry Read-Through
Myriad’s aggressive commercial expansion and focus on differentiated diagnostic launches signal a competitive intensification in oncology and women’s health testing. The company’s early wins in payer coverage and biomarker legislation highlight the importance of reimbursement strategy as a growth lever for diagnostics peers. For the broader sector, the shift toward field specialization and rapid pipeline activation underscores the premium on execution and operational agility, especially as new entrants and incumbents vie for share in underpenetrated, high-value testing markets.